公开(公告)号：US20240185980A1

公开(公告)日：2024-06-06

申请号：US18440058

申请日：2024-02-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY ,  Eric BENJAMIN

IPC: G16H20/17 ,  A61M5/172 ,  G16H40/67

CPC classification number: G16H20/17 ,  A61M5/1723 ,  G16H40/67 ,  A61M2205/18 ,  A61M2205/3584 ,  A61M2205/505 ,  A61M2230/201

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US20240157053A1

公开(公告)日：2024-05-16

申请号：US18498275

申请日：2023-10-31

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR ,  James CAUSEY ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  G16H20/17 ,  A61M2005/1401 ,  A61M2005/1726

Abstract: Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.

公开(公告)号：US20240009392A1

公开(公告)日：2024-01-11

申请号：US18350223

申请日：2023-07-11

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Joshua WILLIAMS ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486

Abstract: Exemplary embodiments may determine anticipated basal insulin delivery action to a user from an insulin delivery device over a future time window. Indications of the anticipated basal insulin delivery action over the future time window may be output to the user. The exemplary embodiments may determine the anticipated basal insulin delivery action over the future time window based on a rate of change (ROC) of glucose level of the user by the insulin delivery device, a most recent (“current”) glucose level for the user and insulin on board (IOB) for the user. The exemplary embodiments may also determine whether the user is likely to experience a undesired high glucose level (e.g., hyperglycemia) and/or an undesired low glucose level (e.g., hypoglycemia) during the future time window. The exemplary embodiments may output recommendations based on the projected glucose levels of the user over the future time window.

公开(公告)号：US20230402149A1

公开(公告)日：2023-12-14

申请号：US18199638

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  William WHITELEY ,  Saeed SALAVATI ,  Yibin ZHENG ,  Mert SEVIL ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61B5/145 ,  A61B5/00

CPC classification number: G16H20/17 ,  A61B5/7275 ,  A61B5/14532

Abstract: Exemplary embodiments may provide for the switching of glucose prediction models responsive to certain conditions. For example, glucose prediction models may be switched responsive to a detected crashing glucose level condition. Exemplary embodiments also may dynamically customize parameters, such as coefficient values, of the glucose prediction model to a user. The exemplary embodiments may customize the glucose prediction model based on the history of glucose levels of the user and the history of insulin deliveries to the user. The exemplary embodiments may determine a set of parameters that provides an improved fit of the parameters to the history of glucose levels and insulin deliveries of the user. The improved fit parameters may be used to adapt the parameter set to the most recent run.

公开(公告)号：US20230372613A1

公开(公告)日：2023-11-23

申请号：US18199476

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52

Abstract: The exemplary embodiments may employ a glucose prediction model (GPM) that is tailored to a user to account for insulin sensitivity or insulin insensitivity. The exemplary embodiments may predict future glucose levels based on past glucose levels for the user. Specifically, the GPM in exemplary embodiments may predict the future glucose level of the user as a weighted sum of most recent glucose level readings from the user. The exemplary embodiments may employ linear regression analysis to determine the values of the weights. These weights customize the GPM of the user based on the user's most recent glucose level history. Due to the customization, the GPM may more accurately predict future glucose levels of the user. As a result, the AID may exhibit better glucose level control for the user. The GPM of the exemplary embodiments may be updated on an ongoing basis.

公开(公告)号：US20230330337A1

公开(公告)日：2023-10-19

申请号：US18300201

申请日：2023-04-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE ,  Jonathan HARDY

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2202/0486

Abstract: Disclosed herein are various embodiments comprising methods to propose or modify a basal profile of a user, wherein the basal profile is delivered by an automatic drug delivery system operating in manual mode or is administered manually by the user. Suggestions of initial basal profiles or modifications to existing basal profiles may be based on previous glucose control outcomes or previous insulin delivery as recorded by the automatic drug delivery system.

公开(公告)号：US20230285671A1

公开(公告)日：2023-09-14

申请号：US18119062

申请日：2023-03-08

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Jonathan HARDY

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2230/201

Abstract: The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.

公开(公告)号：US20230256167A1

公开(公告)日：2023-08-17

申请号：US18186539

申请日：2023-03-20

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Mengdi LI ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H40/60 ,  G16H10/60 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  A61M2205/50 ,  A61M2205/3584 ,  A61M2230/201

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US20230181824A1

公开(公告)日：2023-06-15

申请号：US18159353

申请日：2023-01-25

Applicant: INSULET CORPORATION

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/14244 ,  A61M5/145 ,  A61B5/486

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US20230060939A1

公开(公告)日：2023-03-02

申请号：US17821653

申请日：2022-08-23

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  G16H20/17 ,  G16H20/13 ,  A61B5/145

Abstract: The insulin to carbohydrate ratio (ICR) and the correction factor for a user of a medicament delivery device may be automatically adjusted. The automatic adjustments may tailor the values to the user's actual insulin needs. Various factors may be examined to determine how to adjust the ICR and the correction factor. The identified factors are weighed with the processor to decide whether to increase or decrease the insulin to carbohydrate ratio or the correction factor. The insulin to carbohydrate ratio or the correction factor for the user are adjusted based on the weights of the identified factors. In addition or in the alternative, automatic adjustments of user-requested insulin boluses may be made to requested dosages and timing of deliveries of the insulin boluses. In some instances, the exemplary embodiments may deliver a percentage of the insulin bolus dosage initially and deliver the remaining percentage after a delay to reduce the risk of hypoglycemia for the user.